New immunotherapy drug Keytruda approved by FDA to fight 'tough-to-treat' ...

New immunotherapy drug Keytruda approved by FDA to fight 'tough-to-treat' ...
New immunotherapy drug Keytruda approved by FDA to fight 'tough-to-treat' ...
New immunotherapy drug Keytruda approved by FDA in combination with chemotherapy to fight early form of 'tough-to-treat' breast cancer Keytruda, developed by Merck & Co, has been approved by the FDA in combination with chemotherapy to treat triple negative breast cancer (TNBC) TNBC is a more dangerous form of breast cancer for which there were previously no treatments  Around 10% to 15% of women who are diagnosed with breast cancer have TNBC and it has a higher risk of recurrence  Keytruda has now been approved to combat 30 different types of cancer by the FDA 

View
comments

The U.S. Food and Drug Administration (FDA) had approved a new immunotherapy drug in combination with chemotherapy as a treatment for an early form of a tough-to-treat breast cancer.

Keytruda, developed by Kenilworth, New Jersey-based company Merck & Co Inc, received authorization on Tuesday.

The drug will be used to help treat triple-negative breast cancer (TNBC), an aggressive form of the disease with an increased risk of recurrence. 

Trial data from more than 1,000 patients showed that Keytruda, when used with chemotherapy before surgery and then as a monotherapy after surgery, helped prolong the time that a patient remained free of cancer. 

The combination therapy is the first time that a treatment regimen using an immunotherapy has been approved for patients with early-stage TNBC. 

Keytruda (pictured) has been approved by the FDA to treat TNBC, a form of breast cancer that appears in 10% to 15% of patients

Keytruda (pictured) has been approved by the FDA to treat TNBC, a form of breast cancer that appears in 10% to 15% of patients

'Triple-negative is a difficult-to-treat type of

read more from dailymail.....

NEXT Life-extending drug for sufferers of asbestos lung disease will finally be ...